Inactive Instrument

Highlights ProMIS Neurosciences, Inc. Toronto S.E.

Equities

ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	30/04	CI
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	09/04	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
ProMIS Neurosciences Announces Publication on Novel Target for ALS	20/12	CI
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	20/11	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI

No results for this search